Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. (Q51535042)
Jump to navigation
Jump to search
scientific article published on 4 August 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. |
scientific article published on 4 August 2016 |
Statements
1 reference
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. (English)
1 reference
Crystal S Denlinger
1 reference
Michael Pishvaian
1 reference
Michael A Morse
1 reference
Jennifer McDevitt
1 reference
Jonathan D Norton
1 reference
Song Ren
1 reference
Gabriel J Robbie
1 reference
Patricia C Ryan
1 reference
Serguei Soukharev
1 reference
Haifeng Bao
1 reference
4 August 2016
1 reference
15
1 reference
4
1 reference
345-351
1 reference
Identifiers
1 reference